A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma
A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
Interleukin-13 (IL-13) is a key mediator in the pathogenesis of established asthmatic disease. Tralokinumab is a human monoclonal antibody that blocks IL-13, which may result in improved control of asthma. This study will determine whether the addition of tralokinumab to standard asthma medications results in a reduced rate of asthma exacerbations in subjects with severe asthma.
Inclusion Criteria:
Exclusion Criteria:
Ciudad de Buenos Aires, Argentina
Fujisawa-shi, Japan
Habikino-shi, Japan
Itabashi-ku, Japan
Kahoku-gun, Japan
Kishiwada-shi, Japan
Naka-gun, Japan
Sagamihara-shi, Japan
Sakaide-shi, Japan
Sumida-ku, Japan
Takatsuki-shi, Japan
Tomakomai-shi, Japan